Oral semaglutide is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
The panel discussion is expected to be unusual in more ways than one
When substantive new information or evidence emerges, which might meaningfully alter these clinical points, the four contributing organisations will provide a review and update if necessary
Tirzepatide produces sustained metabolic changes over months, with durability supported by the STEP clinical trial series showing weight reductions of 1522% at maintenance doses
The genes affected by semaglutide included markers of inflammation and plaque stability that are associated with leukocyte recruitment [e.g., interleukin-1 (IL-1) receptor antagonist, IL-6, monocyte chemoattractant protein (CCL2), OPN], leukocyte adhesion [selectin E, vascular cell adhesion molecule-1 (VCAM1)], leukocyte extravasation and plaque stability (e.g., MMP3, MMP13, CCL2), and plaque rupture and hemorrhage (CD163)
These reductions typically mirror weight loss and improved insulin sensitivity rather than direct drug toxicity
